NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Nice find. I think that recent example with Bluebird Bio sounds exactly like what I was discussing that FDA guidance clause allowed for. The question is what goes on between the DMC, LP/NWBO and public communication if such an interim analysis success occurs allowing NWBO to proceed with AA while maintaining a blind. Is a halt still recommended? Is it bypassed? If by passed, is the public told? If the DMC recommends a halt, I think NWBO has to communicate it. So what is the mechanism beyond what you found? Regardless, nice find, I really appreciate that.